It was approved by the FDA in March 2017 as a treatment for [[multiple sclerosis]], and the first FDA approved drug for the primary progressive form of MS; it was discovered and developed and is marketed by [[Hoffmannâ€“La Roche]]'s subsidiary [[Genentech]] under the trade name Ocrevus.<ref name=STATapproval/><ref name=FDAlabel2017>{{cite web|title=Ocrelizumab label|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf|publisher=FDA|accessdate=1 April 2017|date=March 2017}} See [http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761053 FDA index page for BLA 761053] for updates.</ref>  With the approval, the FDA also required the company to conduct several [[Phases of clinical research#Phase IV|Phase IV]] clinical trials to better understand whether the drug is safe and effective in young people, cancer risks, and effects on pregnant women and children they might bear.<ref name=FDABLAapproval>{{cite web|title=BLA Approval Letter|url=https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761053Orig1s000ltr.pdf|publisher=FDA|date=March 28, 2017}}</ref>

 
Ocrelizumab should not be used in people with [[hepatitis B]] infection or a history of severe reaction to this drug.  If someone has an infection or infectious disease, treatment should be delayed until the infection is resolved.   It has not been tested in pregnant women, but based on animal studies does not appear to be safe for pregnant women to take; it is excreted in breast milk and effects on infants are unknown.<ref name=FDAlabel2017/>

 
==Adverse effects ==
